Aurobindo Pharma's Growth Driven by Penicillin G, US Market Not Key Near Term

• Aurobindo Pharma's growth in the next year will primarily be led by its Penicillin G (Pen-G) business, according to analyst Vishal Manchanda.
• The US market is not expected to be a significant immediate driver for Aurobindo Pharma's growth.
• Analyst downplayed the impact of recent US FDA Form 483 observations, noting they are common in the US business.
• Aurobindo Pharma has a history of effectively managing compliance issues, even having faced Official Action Indicated (OAIs) in the past.
• Domestic formulations continue to outperform in the broader sector, with Sun Pharma, Ajanta Pharma, Dr Reddy’s, and Zydus Lifesciences showing strong growth.